Plasma gelsolin protein: A candidate biomarker for hepatitis B-associated liver cirrhosis identified by proteomic approach

Blood Transfusion

Volumn 8, Issue SUPPL. 3, 2010, Pages

  Marrocco, Cristina ^a   Rinalducci, Sara ^a   Mohamadkhani, Ashraf ^b   D'Amici, Gian Maria ^a   Zolla, Lello ^a  

^a UNIVERSITY OF TUSCIA   (Italy)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biomarker discovery; HBV associated liver cirrhosis; Hepatitis B virus (HBV); Human plasma; Inactive chronic HBV infection

Indexed keywords

ACTIN DEPOLYMERIZING FACTOR; ALBUMIN; BIOLOGICAL MARKER; GELSOLIN; IMMUNOGLOBULIN G; PROTEOME;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; FEMALE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER INJURY; MALE; MASS SPECTROMETRY; PILOT STUDY; PROGNOSIS; PROTEIN VARIANT; PROTEOMICS; REPRODUCIBILITY; TWO DIMENSIONAL ELECTROPHORESIS; VALIDATION PROCESS;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GELSOLIN; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MASS SPECTROMETRY; PILOT PROJECTS; PROTEOMICS;

EID: 78049387155     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2010.017S     Document Type: Article

References (45)

1. Seeger C, Mason WS. Hepatitis B Virus Biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
2. Andre F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 2000; 18 (Suppl 1): S20-22.
3. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (Suppl 1): S5-S16. (Pubitemid 39423365)
4. Norman G. Hepatitis B: diagnosis, prevention, and treatment. Clin Chem 1997; 43: 1500-06.
5. Villarejos VM, Visoná KA, Gutiérrez A, Rodríguez A. Role of saliva, urine and feces in the transmission of type B hepatitis. N Engl J Med 1974; 291: 1375-8.
6. Karayiannis P, Novick DM, Lok AS, et al. Heatitis B virus DNA in saliva, urine, and seminal fluid of carriers of hepatitis B e antigen. Br Med J 1985; 290: 1853-5.
7. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007; 85: 16-23
8. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50.
9. Canbay A, Taimr P, Torok N, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003; 83: 655-63.
10. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36: 152-60.
11. Zolla L. Proteomics studies reveal important information on small molecule therapeutics. Drug Discovery Today 2008; 13: 1042-51.
12. Anderson LN, Anderson NG. The Human Plasma Proteome: History, Character, and Diagnostic Prospects. Mol Cell Proteomics 2002; 1: 845-67.
13. Adkins JN, Varnum SM, Auberry KJ, el al. Toward a Human Blood Serum Proteome analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002; 1: 947-55.
14. Ahmed FE. Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry. J Sep Sci 2009; 32: 771-798.
15. Boschetti E, Righetti PG. The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. J Proteomics 2008; 71: 255-264.
16. Sennels L, Salek M, Lomas L, et al. Proteomic Analysis of Human Blood Serum Using Peptide Library Beads. J Proteome Res 2007; 6: 4055-62. (Pubitemid 350032568)
17. Poutchi H, Mohamadkhani A, Bowden S, et al. Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease. J Viral Hepat 2008; 15: 753-60.
18. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
20. Candiano G, Bruschi M, Musante L, et al. Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 2004; 25: 1327-33.
21. Shevchenko A, Tomas H, Havlis J, et al. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 2007; 1: 2856-60.
22. Rossi E, Adams LA, Bulsara M, Jaffrey GP. Assessing liver fibrosis whit serum marker models. Clin Biochem Rev 2007; 28: 3-10.
23. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006; 43 (Suppl 1): S113-20.
24. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999; 45 (Suppl 4): IV1-11.
25. Scheuer PJ. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 2003; 38: 1356-8.
26. Soloway RD, Baggestoss AH, Schoenfield LJ, Summerskill WH. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1971; 16: 1082-6.
27. Poon TC, Johnson PJ. Proteome analysis and its impact on the discovery of serological tumor markers. Clin Chim Acta 2001; 313: 231-9.
28. Poon TC, Yip TT, Chan AT, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003; 49: 752-60.
29. He QY, Lau GK, Zhou Y, et al. Serum biomarkers of hepatitis B virus infected liver inflammation: a proteomic study. Proteomics 2003; 3: 666-74. (Pubitemid 36570257)
30. Steel LF, Shumpert D, Trotter M, et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 2003; 3: 601-9.
31. Cui J, Kang X, Dai Z, et al. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification. J Cancer Res Clin Oncol 2007; 133: 825-34.
32. Poon TC, Hui AY, Chan HL, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005; 51: 328-35.
33. He QY, Zhu R, Lei T, et al. Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma. J Cell Biochem 2008; 103: 740-52. (Pubitemid 351240611)
34. Feng JT, Liu YK, Song HY, et al. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 2005; 5: 4581-8.
35. Li N, Long Y, Fan X, et al. Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues. J Exp Clin Cancer Res 2009; 28: 122.
36. Na K, Lee EY, Lee HJ, et al. Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma. Proteomics 2009; 9: 3989-99.
37. Ren F, Chen Y, Wang Y, et al. Comparative serum proteomic analysis of patients with acute-on-chronic liver failure: alpha-1-acid glycoprotein maybe a candidate marker for prognosis of hepatitis B virus infection. J Viral Hepat 2010; DOI 10.1111/j.1365-2893.2009.01242.x.
38. Bucki R, Levental I, Kulakowska A, Janmey PA. Plasma gelsolin: function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci 2008; 9: 541-51.
39. Lind SE, Smith DB, Janmey PA, Stossel TP. Depression of gelsolin levels and detection of gelsolin-actin complexes in plasma of patients with acute lung injury. Am Rev Respir Dis 1988; 138: 429-34.
40. Wang H, Cheng B, Chen Q, et al. Time course of plasma gelsolin concentrations during severe sepsis in critically ill surgical patients. Crit Care 2008; 12: R106.
41. Huang S, Rhoads SL, DiNubile MJ. Temporal association between serum gelsolin levels and clinical events in a patient with severe falciparum malaria. Clin Infect Dis 1997; 24: 951-4.
42. Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med 1997; 25: 594-8.
43. Mounzer KC, Moncure M, Smith YR, DiNubile MJ. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med 1999; 160: 1673-81.
44. Spinardi L, Witke W. Gelsolin and disease. Subcell Biochem 2007; 45: 55-69.
45. Fernández-Irigoyen J, Santamaría E, Sesma L, et al. Oxidation of specific methionine and tryptophan residues of apolipoprotein A-I in hepatocarcinogenesis. Proteomics 2005; 5: 4964-72. (Pubitemid 43016915)